Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer
10.3760/cma.j.cn371439-20230428-00120
- VernacularTitle:靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用
- Author:
Xiaopeng YU
1
;
Qingqing FENG
;
Wenfei ZHAO
;
Wenwen ZHAO
;
Hongmei WEI
Author Information
1. 潍坊医学院临床医学院，潍坊 261053
- Keywords:
Stomach neoplasms;
Receptor, erbB-2;
Immune checkpoint inhibitors
- From:
Journal of International Oncology
2023;50(10):631-635
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor 2 (HER2), programmed death-1 and programmed death-ligand 1 are related to the proliferation, invasion and metastasis of various tumor cells. A variety of antibodies and small molecule drugs targeting HER2 have achieved considerable results in clinical practice. Immune checkpoint inhibitors targeting programmed death-1 and programmed death-ligand 1 have significant effects in clinical application. In the KEYNOTE-811 trial, the combination of immune checkpoint inhibitors and targeted therapy has achieved encouraging results in HER2-positive advanced gastric cancer.
